These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 11803844)

  • 1. [Malignant hyperthermia: new developments in diagnosis and clinical management].
    Dépret T; Krivosic-Horber R
    Ann Fr Anesth Reanim; 2001 Dec; 20(10):838-52. PubMed ID: 11803844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Malignant hyperthermia].
    Urwyler A; Hartung E
    Anaesthesist; 1994 Aug; 43(8):557-69. PubMed ID: 7978181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant hyperthermia.
    Ben Abraham R; Adnet P; Glauber V; Perel A
    Postgrad Med J; 1998 Jan; 74(867):11-7. PubMed ID: 9538480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hyperthermia.
    Rosenberg H; Davis M; James D; Pollock N; Stowell K
    Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant hyperthermia: clinical and molecular aspects.
    Correia AC; Silva PC; da Silva BA
    Rev Bras Anestesiol; 2012; 62(6):820-37. PubMed ID: 23176990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Malignant hyperthermia--diagnostics, treatment and anaesthetic management].
    Schuster F; Müller-Reible CR
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Nov; 44(11-12):758-63; quiz 764. PubMed ID: 19918708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology and Treatment of Malignant Hyperthermia.
    Gregory H; Weant KA
    Adv Emerg Nurs J; 2021 Apr-Jun 01; 43(2):102-110. PubMed ID: 33915557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding of malignant hyperthermia: genesis, prevention, and treatment.
    Katz DN
    CRNA; 1992 May; 3(2):54-63. PubMed ID: 1483145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Hyperthermia Susceptibility and Fitness for Duty.
    Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
    Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
    Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
    Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
    Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
    Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for malignant hyperthermia susceptibility.
    Anderson IL; Rawstron RE; Dunlop DJ
    N Z Med J; 1980 Jun; 91(661):417-9. PubMed ID: 6930029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.
    Carlson KJ; Sun SA; Swan C; Koenig M; Derkay CS
    Int J Pediatr Otorhinolaryngol; 2022 Aug; 159():111187. PubMed ID: 35660936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.
    Glahn KP; Ellis FR; Halsall PJ; Müller CR; Snoeck MM; Urwyler A; Wappler F;
    Br J Anaesth; 2010 Oct; 105(4):417-20. PubMed ID: 20837722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.